Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Partners Research Building, Cambridge, MA, USA.
EMBO Mol Med. 2011 Dec;3(12):701-12. doi: 10.1002/emmm.201100175. Epub 2011 Sep 23.
The death of cardiac myocytes diminishes the heart's pump function and is a major cause of heart failure, one of the dominant causes of death worldwide. Other than transplantation, there are no therapies that directly address the loss of cardiac myocytes, which explains the current excitement in cardiac regeneration. The field is evolving in two important directions. First, although endogenous mammalian cardiac regeneration clearly seems to decline rapidly after birth, it may still persist in adulthood. The careful elucidation of the cellular and molecular mechanisms of endogenous heart regeneration may therefore provide an opportunity for developing therapeutic interventions that amplify this process. Second, recent breakthroughs have enabled reprogramming of cells that were apparently terminally differentiated, either by dedifferentiation into pluripotent stem cells or by transdifferentiation into cardiac myocytes. These achievements challenge our conceptions of what is possible in terms of heart regeneration. In this review, we discuss the current status of research on cardiac regeneration, with a focus on the challenges that hold back therapeutic development.
心肌细胞的死亡会降低心脏的泵功能,是心力衰竭的主要原因之一,心力衰竭是全球主要死亡原因之一。除了移植,目前没有任何治疗方法可以直接针对心肌细胞的损失,这解释了心脏再生领域目前的兴奋点。该领域正在向两个重要方向发展。首先,尽管内源性哺乳动物心脏再生在出生后显然迅速下降,但它可能仍在成年期持续存在。因此,仔细阐明内源性心脏再生的细胞和分子机制可能为开发增强这一过程的治疗干预措施提供机会。其次,最近的突破使细胞重编程成为可能,这些细胞显然已经终末分化,要么通过去分化为多能干细胞,要么通过转分化为心肌细胞。这些成就挑战了我们对心脏再生的可能性的概念。在这篇综述中,我们讨论了心脏再生研究的现状,重点讨论了阻碍治疗发展的挑战。